Impact of [11C]methionine Positron Emission Tomography for Target Definition of Glioblastoma Multiforme in Radiation Therapy Planning
Overview
Authors
Affiliations
Purpose: The purpose of this work was to define the optimal margins for gadolinium-enhanced T(1)-weighted magnetic resonance imaging (Gd-MRI) and T(2)-weighted MRI (T(2)-MRI) for delineating target volumes in planning radiation therapy for postoperative patients with newly diagnosed glioblastoma multiforme (GBM) by comparison to carbon-11-labeled methionine positron emission tomography ([(11)C]MET-PET) findings.
Methods And Materials: Computed tomography (CT), MRI, and [(11)C]MET-PET were separately performed for radiation therapy planning for 32 patients newly diagnosed with GBM within 2 weeks after undergoing surgery. The extent of Gd-MRI (Gd-enhanced clinical target volume [CTV-Gd]) uptake and that of T(2)-MRI of the CTV (CTV-T(2)) were compared with the extent of [(11)C]MET-PET (CTV--[(11)C]MET-PET) uptake by using CT--MRI or CT--[(11)C]MET-PET fusion imaging. We defined CTV-Gd (x mm) and CTV-T(2) (x mm) as the x-mm margins (where x = 0, 2, 5, 10, and 20 mm) outside the CTV-Gd and the CTV-T(2), respectively. We evaluated the relationship between CTV-Gd (x mm) and CTV-- [(11)C]MET-PET and the relationship between CTV-T(2) (x mm) and CTV-- [(11)C]MET-PET.
Results: The sensitivity of CTV-Gd (20 mm) (86.4%) was significantly higher than that of the other CTV-Gd. The sensitivity of CTV-T(2) (20 mm) (96.4%) was significantly higher than that of the other CTV-T(2) (x = 0, 2, 5, 10 mm). The highest sensitivity and lowest specificity was found with CTV-T(2) (x = 20 mm).
Conclusions: It is necessary to use a margin of at least 2 cm for CTV-T(2) for the initial target planning of radiation therapy. However, there is a limit to this setting in defining the optimal margin for Gd-MRI and T(2)-MRI for the precise delineation of target volumes in radiation therapy planning for postoperative patients with GBM.
Li Y, Wu C, Long X, Wang X, Gao W, Deng K MedComm (2020). 2024; 5(12):e70014.
PMID: 39640361 PMC: 11617595. DOI: 10.1002/mco2.70014.
Debreczeni-Mate Z, Toro I, Simon M, Gal K, Barabas M, Sipos D Diagnostics (Basel). 2024; 14(9).
PMID: 38732378 PMC: 11083337. DOI: 10.3390/diagnostics14090964.
Yamamura T, Tamura K, Kobayashi D, Inaji M, Toyama Y, Wakimoto H J Neurooncol. 2024; 168(2):355-365.
PMID: 38557927 DOI: 10.1007/s11060-024-04661-y.
Shahzadi I, Seidlitz A, Beuthien-Baumann B, Zwanenburg A, Platzek I, Kotzerke J Sci Rep. 2024; 14(1):4576.
PMID: 38403632 PMC: 10894870. DOI: 10.1038/s41598-024-55092-8.
De Marco R, Pesaresi A, Bianconi A, Zotta M, Deandreis D, Morana G Cancers (Basel). 2023; 15(1).
PMID: 36612085 PMC: 9817716. DOI: 10.3390/cancers15010090.